keyword
MENU ▼
Read by QxMD icon Read
search

Ulipristal acetate

keyword
https://www.readbyqxmd.com/read/28292452/sometimes-you-do-get-a-second-chance-emergency-contraception-for-adolescents
#1
REVIEW
Ellen S Rome, Veronica Issac
Unplanned or unintended pregnancy remains a significant challenge for adolescents; many teens who plan ahead but opt not to choose long-acting reversible contraceptive methods have high failure rates with condom usage, oral contraceptives, and other less long-acting methods. Emergency contraception (EC) remains a necessity for those adolescents seeking a second chance to prevent the unintended consequences of unplanned sexual activity. At present, 5 postcoital methods remain available as EC globally: intrauterine devices, ulipristal acetate, a selective progesterone modulator, mifepristone; levonorgestrel, and ethinyl estradiol plus levonorgestrel or norgestrel (rarely used now that progestin only methods are more readily available)...
April 2017: Pediatric Clinics of North America
https://www.readbyqxmd.com/read/28267814/safety-after-extended-repeated-use-of-ulipristal-acetate-for-uterine-fibroids
#2
Bart C J M Fauser, Jacques Donnez, Philippe Bouchard, David H Barlow, Francisco Vázquez, Pablo Arriagada, Sven O Skouby, Santiago Palacios, Janusz Tomaszewski, Boguslaw Lemieszczuk, Alistair R W William
OBJECTIVE: To assess long term safety of extended repeated 3-month courses of ulipristal acetate (UPA) 10 mg/day, for up to 8 courses, with focus on endometrial and laboratory safety parameters. METHODS: This long-term, multi-center, open-label cohort, follow up study consisted of up to 8 consecutive 3-month courses of daily UPA 10 mg, each separated by a drug free period of 2 spontaneous menstrual bleeds. Sixty-four pre-menopausal women, with moderate to severe symptomatic uterine myoma(s) and heavy bleeding were enrolled and were studied for approximately 4 years...
2017: PloS One
https://www.readbyqxmd.com/read/28262240/heavy-menstrual-bleeding-an-update-on-management
#3
Joanna Davies, Rezan A Kadir
Heavy menstrual bleeding (HMB) is defined as excessive menstrual blood loss (MBL) >80 mL per cycle, that interferes with a woman's physical, emotional, social wellbeing and quality of life. Aetiology is due to underlying uterine pathologies, coagulopathy, ovulation dysfunction, or iatrogenic. Up to 20% of women with HMB will have an underlying inherited bleeding disorder (IBD). Assessment of HMB should entail a menstrual and gynaecological history and a bleeding score to distinguish those women who require additional haematological investigations...
March 2017: Thrombosis Research
https://www.readbyqxmd.com/read/28250723/ulipristal-acetate-before-high-complexity-endoscopic-hysteroscopic-laparoscopic-myomectomy-a-mini-review
#4
REVIEW
Włodzimierz Baranowski
Uterine myomas (fibromas, leiomyomas) are the most common tumours in women, and their clinical signs and symptoms are presented by 25-40% of patients with these benign tumours. According to current guidelines, the armamentarium for myoma management consists of: medical therapy (GnRH, SPRMs), non-surgical alternatives including uterine artery embolisation (UAE), vaginal temporary occlusion of uterine arteries using clamp-like device or MRgFUS technique, and surgical treatment (including minimally invasive techniques)...
December 2016: Przeglad Menopauzalny, Menopause Review
https://www.readbyqxmd.com/read/28238840/study-of-the-effect-of-ulipristal-acetate-on-human-sperm-ability-to-interact-with-tubal-tissue-and-cumulus-oocyte-complexes
#5
Carlos Zumoffen, Matías D Gómez-Elías, Adriana M Caille, Luis Bahamondes, Patricia S Cuasnicú, Débora J Cohen, María José Munuce
OBJECTIVE: Ulispristal acetate (UPA) is a selective progesterone receptor modulator widely used for emergency contraception (EC). The described main mechanism of action is by inhibiting or delaying ovulation; however, the postovulatory effects of the drug are still on debate. Therefore, the aim of this study was to determine whether UPA could interfere with human sperm fertilizing ability. STUDY DESIGN: Human motile spermatozoa were incubated under capacitating conditions with or without UPA, and then used to inseminate human tubal explants, mouse cumulus-oocyte complexes and zona-free hamster eggs...
February 24, 2017: Contraception
https://www.readbyqxmd.com/read/28219738/ulipristal-acetate-administration-at-mid-cycle-changes-gene-expression-profiling-of-endometrial-biopsies-taken-during-the-receptive-period-of-the-human-menstrual-cycle
#6
Saúl Lira-Albarrán, Marta Durand, Marco F Larrea-Schiavon, Leticia González, David Barrera, Claudia Vega, Armando Gamboa-Domínguez, Claudia Rangel, Fernando Larrea
The aim of this study was to analyze the effects of mid-cycle administration of Ulipristal acetate (UPA) on gene expression in endometrial biopsies taken during the receptive phase of the cycle. Fourteen healthy menstruating women were studied during 14 control non-treated and 12 treated cycles with a single dose of 30 mg UPA when follicle diameter reached 20 mm. Ovulation in both treated and control cycles was confirmed by serial determinations of serum LH, progesterone and vaginal ultrasound. An endometrial biopsy at day LH+7, in each cycle, was taken for RNA microarray and qPCR analysis or prepared for histological and immunohistochemistry studies...
February 20, 2017: Molecular and Cellular Endocrinology
https://www.readbyqxmd.com/read/28217674/uterine-fibroid-shrinkage-after-short-term-use-of-selective-progesterone-receptor-modulator-or-gonadotropin-releasing-hormone-agonist
#7
Min Jin Lee, Bo Seong Yun, Seok Ju Seong, Mi-La Kim, Yong Wook Jung, Mi Kyoung Kim, Hyo Sook Bae, Da Hee Kim, Ji Young Hwang
OBJECTIVE: The aim of this study was to evaluate the effect of short-term use of selective progesterone receptor modulator (SPRM) or gonadotropin-releasing hormone (GnRH) agonist on uterine fibroid shrinkage among Korean women. METHODS: This retrospective study involved 101 women with symptomatic uterine fibroids who received ulipristal acetate (SPRM, n=51) and leuprolide acetate (GnRH agonist, n=50) for 3 months between November 2013 and February 2015. The fibroid volume was measured both before and after treatment using ultrasonography, computed tomography, and magnetic resonance imaging...
January 2017: Obstetrics & Gynecology Science
https://www.readbyqxmd.com/read/28185997/rationale-and-design-of-asteroid-2-a-randomized-placebo-and-active-comparator-controlled-study-to-assess-the-efficacy-and-safety-of-vilaprisan-in-patients-with-uterine-fibroids
#8
Christian Seitz, Žana Bumbuliene, Ana Rosa Costa, Oskari Heikinheimo, Andrea Heweker, Robert Hudeček, Yves Jacquemyn, Gian Benedetto Melis, Pooja Parashar, Tomasz Rechberger, Antonio Cano Sánchez, Bart van Aken, János Zatik, Kristina Gemzell-Danielsson
BACKGROUND: Uterine fibroids (UFs) may be treated with progesterone receptor modulators (PRMs), which have been shown to reduce heavy menstrual bleeding and the size of UFs. To date, one PRM (ulipristal acetate) has received regulatory approval for the treatment of UFs; therapy comprises intermittent treatment courses of up to 3months each, followed by a break to allow two menstruations to occur. We report the design of ASTEROID (Assess Safety and efficacy of vilaprisan in patients with uTERine fibrOIDs) 2, a phase 2 study examining the efficacy and safety of a novel PRM, vilaprisan, in women with UFs...
April 2017: Contemporary Clinical Trials
https://www.readbyqxmd.com/read/28169130/the-history-and-use-of-the-progesterone-receptor-modulator-ulipristal-acetate-for-heavy-menstrual-bleeding-with-uterine-fibroids
#9
REVIEW
Philippe Bouchard, Nathalie Chabbert-Buffet
Progesterone receptor modulators (PRM) or selective progesterone receptor modulators have two remarkable effects in treated women. They considerably suppress endometrial bleeding by incompletely understood mechanisms, and when administered in women with symptomatic fibroids, they produce a significant and potentially long-term decrease in fibroid volume. The crucial advantage of this therapy lies with the absence of suppression of ovarian oestrogen secretion, which is in contrast to GnRH agonists. Long-term treatments have proven to be useful, especially in women approaching the menopausal transition...
December 18, 2016: Best Practice & Research. Clinical Obstetrics & Gynaecology
https://www.readbyqxmd.com/read/28130434/selective-progesterone-receptor-modulator-sprm-ulipristal-acetate-upa-and-its-effects-on-the-human-endometrium
#10
L H R Whitaker, A A Murray, R Matthews, G Shaw, A R W Williams, P T K Saunders, H O D Critchley
STUDY QUESTION: What is the impact of administration of the selective progesterone receptor modulator (SPRM), ulipristal acetate (UPA) on the endometrium of women with fibroids? SUMMARY ANSWER: UPA administration altered expression of sex-steroid receptors and progesterone-regulated genes and was associated with low levels of glandular and stromal cell proliferation. WHAT IS KNOWN ALREADY: Administration of all SPRM class members results in PAEC (progesterone receptor modulator associated endometrial changes)...
January 26, 2017: Human Reproduction
https://www.readbyqxmd.com/read/28126541/temporary-removal-pharmacokinetics-of-levonorgestrel-and-ulipristal-acetate-emergency-contraception-in-women-with-normal-and-obese-body-mass-index
#11
Piyapa Praditpan, Angie Hamouie, Cale N Basaraba, Renu Nandakumar, Serge Cremers, Anne R Davis, Carolyn L Westhoff
The publisher regrets that this article has been temporarily removed. A replacement will appear as soon as possible in which the reason for the removal of the article will be specified, or the article will be reinstated. The full Elsevier Policy on Article Withdrawal can be found at http://www.elsevier.com/locate/withdrawalpolicy.
January 23, 2017: Contraception
https://www.readbyqxmd.com/read/27990057/ulipristal-acetate-for-fibroids
#12
REVIEW
(no author information available yet)
No abstract text is available yet for this article.
December 2016: Australian Prescriber
https://www.readbyqxmd.com/read/27990056/ulipristal-acetate-for-emergency-contraception
#13
REVIEW
(no author information available yet)
No abstract text is available yet for this article.
December 2016: Australian Prescriber
https://www.readbyqxmd.com/read/27970726/cost-utility-analysis-of-ulipristal-acetate-5-mg-for-long-term-treatment-of-moderate-to-severe-symptoms-of-uterine-fibroids-in-portugal
#14
A Paquete, M Lehmann, D P Silva, C G Pinto
No abstract text is available yet for this article.
November 2016: Value in Health: the Journal of the International Society for Pharmacoeconomics and Outcomes Research
https://www.readbyqxmd.com/read/27970716/budget-impact-of-ulipristal-acetate-5mg-in-pre-operative-treatment-of-uterine-fibroids-an-analysis-based-on-public-data-on-hospital-stays-in-france
#15
M Trancart, M Lehmann, A Lafuma
No abstract text is available yet for this article.
November 2016: Value in Health: the Journal of the International Society for Pharmacoeconomics and Outcomes Research
https://www.readbyqxmd.com/read/27918164/-the-possibility-of-using-progesterone-receptor-modulators-in-the-treatment-of-myomas
#16
O Šimetka, J Klát, S Bajsová
OBJECTIVE: To summarize the knowledge about the effect of selective progesterone receptor modulators and their use in the treatment of myomas in women of childbearing age and in perimenopause. DESIGN: Review article. RESULTS: Long-term treatment with ulipristal acetate maximizes its effectiveness, it helps to achieve faster bleeding control and increases the number of pa-tients with fibroid volume reduction of more than 50%. Ulipristal acetate is the most effective drug in the medical treatment of myomas and its use will change the approach to surgical treatment...
2016: Ceská Gynekologie
https://www.readbyqxmd.com/read/27914766/histomorphological-changes-in-endometriosis-in-a-patient-treated-with-ulipristal-a-case-report
#17
J Bateman, O Bougie, S Singh, S Islam
BACKGROUND: Selective progesterone receptor modulators have shown efficacy in the treatment of endometriosis, however they are not currently licensed in Canada for this purpose. Their histomorphological effects have been well documented in the endometrium, but not in endometriosis. CASE REPORT: The patient presented with uterine fibroids and heavy menstrual bleeding, and was treated with ulipristal acetate over three 90-day courses. She eventually elected to undergo definitive surgical management...
January 2017: Pathology, Research and Practice
https://www.readbyqxmd.com/read/27898340/real-world-data-of-1473-patients-treated-with-ulipristal-acetate-for-uterine-fibroids-premya-study-results
#18
Hervé Fernandez, Torsten Schmidt, Martin Powell, Ana Patrícia Freitas Costa, Pablo Arriagada, Christian Thaler
OBJECTIVES: To characterize and describe treatment with Ulipristal acetate (UPA) in a pre-operative setting and to evaluate the safety, effectiveness, and Health Related Quality of Life (HRQoL) outcomes in a population treated according to standard clinical practice in the EU. STUDY DESIGN: Multi-centre, prospective, non-interventional study (PREMYA) of patients diagnosed with moderate to severe symptoms of uterine fibroids and undergoing a pre-operative treatment with UPA (Esmya(®)) at 73 clinical practice sites within the EU...
January 2017: European Journal of Obstetrics, Gynecology, and Reproductive Biology
https://www.readbyqxmd.com/read/27896473/experience-with-oral-emergency-contraception-since-the-otc-switch-in-germany
#19
Marion Kiechle, Miriam Neuenfeldt
PURPOSE: In March 2015, the oral emergency contraceptives levonorgestrel (LNG) and ulipristal acetate (UPA) were released from prescription-only status in Germany. The main research question is to analyse whether the OTC status of oral emergency contraceptives has an influence on the patterns of use. METHODS: All information is based on searches for public domain sources on emergency contraception. Searches were made for scientific publications, statistics, and surveys...
March 2017: Archives of Gynecology and Obstetrics
https://www.readbyqxmd.com/read/27889055/medical-or-surgical-management-of-fibroids-an-internet-survey-of-gynecologists-views
#20
Elisa Pazzaglia, Julie Praet, Jean Vandromme, Serge Rozenberg
AIM: To assess the attitudes of gynecologists toward symptomatic fibroids and analyze which factors influence their choice of treatment. MATERIAL AND METHOD: We surveyed the attitude of Belgian gynecologists toward patients' cases. We used a vignette of a woman with symptomatic fibroids and modified 3 factors: her age, her parity and her desire for pregnancy, thereby establishing 12 different cases. We ensured that each gynecologist (n=1437) received one case, chosen randomly, by email...
January 2017: Maturitas
keyword
keyword
119605
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"